Cyclarity Therapeutics

Cyclarity Therapeutics

Private
Novato, CaliforniaHealthcare & Life Scienceshttps://cyclaritytx.com/

Last Round

Series A

Dec 30, 2024

Est. Valuation

$30.4M

Total Funding Raised

$24.35M

Momentum Score

100 /100

Company Overview

Cyclarity Therapeutics is a biotechnology company that develops drugs to prevent and treat age-related conditions such as atherosclerosis by targeting and removing toxic forms of cholesterol.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical AI

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Infrastructure

Keywords

atherosclerosis therapyengineered cyclodextrindisease modifying therapyUDP-003plaque reversalclinical stage biotechlongevity biotech7-ketocholesterol7KCcardiovascular diseaseoxidized cholesterolAI drug discoverygerosciencecomputational chemistryacute coronary syndromeACS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cyclarity Therapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Cyclarity Therapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series ADec 30, 2024
SAFEJul 19, 2023
SeedSep 23, 2021
SeedNov 14, 2019

Key People

Founding team and executive leadership

Michael Kope

CEO Corporate Affairs

Executive Team

Cyclarity Therapeutics Investors

Notable investors and investment history

InvestorRounds
Ki Tua FundSeries A
Kizoo Technology CapitalSeed
VitaDAOSAFE, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 26, 2026

    Grew 19% QoQ from 16 to 19 employees.

  • Apr 21, 2026

    Monthly visitors increased 34% MoM, reaching 2.9K.

Cyclarity Therapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cyclarity Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cyclarity Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNovato, California
Employee Range19
Year Founded2019
Last FundingDec 30, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.